Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 USP26 regulates TGF-β signalling by deubiquitinating and stabilizing SMAD7; not applicable in glioblastoma.

Literature DB >> 31858693

USP26 regulates TGF-β signalling by deubiquitinating and stabilizing SMAD7; not applicable in glioblastoma.

Thomas Mb Ware¹, Hong-Jian Zhu¹.

Abstract

Comment on "USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7" by Kit Leng Lui et al.

Entities: Disease Gene

Mesh：

Substances：

Year: 2019 PMID： 31858693 PMCID： PMC6945060 DOI： 10.15252/embr.201847030

Source DB: PubMed Journal: EMBO Rep ISSN： 1469-221X Impact factor: 8.807

11 in total

1. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300

Review 2. TGF-β signalling and its role in cancer progression and metastasis.

Authors: Yvette Drabsch; Peter ten Dijke
Journal: Cancer Metastasis Rev Date: 2012-12 Impact factor: 9.264

3. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer.

Authors: Alexandre Calon; Enza Lonardo; Antonio Berenguer-Llergo; Elisa Espinet; Xavier Hernando-Momblona; Mar Iglesias; Marta Sevillano; Sergio Palomo-Ponce; Daniele V F Tauriello; Daniel Byrom; Carme Cortina; Clara Morral; Carles Barceló; Sebastien Tosi; Antoni Riera; Camille Stephan-Otto Attolini; David Rossell; Elena Sancho; Eduard Batlle
Journal: Nat Genet Date: 2015-02-23 Impact factor: 38.330

Review 4. The role of transforming growth factor-beta in primary brain tumors.

Authors: Jeremy N Rich
Journal: Front Biosci Date: 2003-01-01

5. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors: Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal: Cancer Cell Date: 2007-02 Impact factor: 31.743

6. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors: Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743

Review 7. TGFbeta in Cancer.

Authors: Joan Massagué
Journal: Cell Date: 2008-07-25 Impact factor: 41.582

8. Heterogeneous activation of the TGFbeta pathway in glioblastomas identified by gene expression-based classification using TGFbeta-responsive genes.

Authors: Xie L Xu; Ann M Kapoun
Journal: J Transl Med Date: 2009-02-03 Impact factor: 5.531

2. Response to: USP26 regulates TGF-β signalling by deubiquitinating and stabilizing SMAD7; not applicable in glioblastoma.

2 in total